Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125398531 | 12539853 | 1 | I | 20160623 | 20160708 | 20160708 | EXP | US-CIPLA LTD.-2016US08468 | CIPLA | ATER JL, XIA C, MAZEWSKI CM, BOOTH TN, FREYER DR, PACKER RJ, ET AL. NONRANDOMIZED COMPARISON OF NEUROFIBROMATOSIS TYPE 1 AND NON-NEUROFIBROMATOSIS TYPE 1 CHILDREN WHO RECEIVED CARBOPLATIN AND VINCRISTINE FOR PROGRESSIVE LOW-GRADE GLIOMA: A REPORT FROM THE CHILDREN^S ONCOLOGY GROUP. CANCER. 2016;122:1928 TO 1936 | 0.00 | Y | 0.00000 | 20160708 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125398531 | 12539853 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Unknown | UNK | 77383 | INFUSION | |||||||||
| 125398531 | 12539853 | 2 | SS | Vincristine | VINCRISTINE | 1 | Unknown | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125398531 | 12539853 | 1 | Glioma |
| 125398531 | 12539853 | 2 | Glioma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125398531 | 12539853 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125398531 | 12539853 | Death |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |